?IIb-Integrin (CD41) associated with blood eosinophils is a potential biomarker for disease activity in eosinophilic esophagitis - 08/06/20
Doi : 10.1016/j.jaci.2020.01.022
Mats W. Johansson, PhD a 
, Elizabeth M. McKernan, BS b, Paul S. Fichtinger, BS b, Evelyn L. Angulo, MD b, Jennifer L. Bagley, RN b, Kristine E. Lee, MS c, Michael D. Evans, MS c, ∗, Luis D. Lomeli, MD b, Deane F. Mosher, MD a, b, Shelly M. Cook, MD d, Eric A. Gaumnitz, MD b, Sameer K. Mathur, MD, PhD, FAAAAI b
, Elizabeth M. McKernan, BS b, Paul S. Fichtinger, BS b, Evelyn L. Angulo, MD b, Jennifer L. Bagley, RN b, Kristine E. Lee, MS c, Michael D. Evans, MS c, ∗, Luis D. Lomeli, MD b, Deane F. Mosher, MD a, b, Shelly M. Cook, MD d, Eric A. Gaumnitz, MD b, Sameer K. Mathur, MD, PhD, FAAAAI b a Department of Biomolecular Chemistry, University of Wisconsin, Madison, Wis
b Department of Medicine, University of Wisconsin, Madison, Wis
c Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wis
d Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Wis
| This study was funded by the National Institutes of Health (grants R21 AI122103 [to S.K.M., E.A.G., and M.W.J.] and T32 AI007635 [to E.L.A.]); Program Project (grant P01 HL088594 [to N.J. Jarjour, D.F.M., and S.K.M.]); Clinical and Translational Science Award (grant U11 RR025011 [to M. K. Drezner]), and University of Wisconsin Carbone Cancer Center (support grant P30 CA014520 [to H. H. Bailey]). The funding source had no involvement in the study design; the data collection, analysis, or interpretation; the writing of the report; or the decision to submit the article for publication. |
|
| Disclosure of potential conflict of interest: M. W. Johansson reports receiving a grant from Hoffmann-La Roche, having received a speaker fee and been an advisory board member for Genentech, and receiving consulting fees from Guidepoint Global unrelated to this work. S. K. Mathur reports receiving consulting and speaker fees from AstraZeneca unrelated to this work. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 145 - N° 6
P. 1699-1701 - Giugno 2020 Ritorno al numero
Articolo precedente
- Severe combined immunodeficiency caused by inositol-trisphosphate 3-kinase B (ITPKB) deficiency
- Abduarahman Almutairi, Jacqueline G. Wallace, Faris Jaber, Mohammed F. Alosaimi, Jennifer Jones, Mohamed T.H. Sallam, M.H. Elnagdy, Janet Chou, Ali Sobh, Raif S. Geha
- Serum IL-6: A biomarker in childhood asthma?
- Daniel J. Jackson, Leonard B. Bacharier, Agustin Calatroni, Michelle A. Gill, Jack Hu, Andrew H. Liu, Lisa M. Wheatley, James E. Gern, Rebecca S. Gruchalla, Gurjit K. Khurana Hershey, Meyer Kattan, Carolyn M. Kercsmar, Haejin Kim, George T. O’Connor, Shilpa Patel, Jacqueline A. Pongracic, Robert A. Wood, William W. Busse
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?